Table 2.
Total cohort screening history.
| HCI | U of M | Penn | Total | |
|---|---|---|---|---|
| Total cohort | ||||
| Total subjects (n) | 100 | 95 | 68 | 263 |
| Imaging screens (n) | 180 | 186 | 125 | 491 |
| Screens per subject (mean±SD) | 1.80±1.17 | 1.96±1.24 | 1.84±1.23 | 1.87±1.22 |
| Range screens per subject (n) | 1-6 | 1-6 | 1-7 | 1-7 |
| Screens including biochemistry (n (% screens)) | 117 (65%) | 135 (73%) | 91 (73%) | 343 (70%) |
| Follow-up time, years (mean±SD) | 1.58±2.42 | 2.04±2.69 | 1.82±3.22 | 1.81±2.75 |
| Subjects with ≥2 screens (n (%)) | 44 (44%) | 47 (49%) | 32 (47%) | 123 (47%) |
| Follow-up time, years (mean±SD) | 3.60±2.47 | 4.13±2.45 | 3.86±3.75 | 3.87±2.86 |
| Subjects with ≥3 screens (n (%)) | 20 (20%) | 24 (25%) | 15 (22%) | 59 (22%) |
| Follow-up time, years (mean±SD) | 5.22±2.21 | 5.72±2.34 | 5.53±4.91 | 5.50±3.17 |
| No prior history of PGL/PCC | ||||
| Subjects (n (% of total subjects)) | 83 | 59 | 52 | 194 (74%) |
| Imaging Screens (n (% of total screens)) | 149 | 98 | 87 | 334 (68%) |
| Prior history of PGL/PCC | ||||
| Subjects (n (% of total total)) | 17 | 36 | 16 | 69 (26%) |
| Imaging Screens (n (% of total screens)) | 31 | 88 | 38 | 157 (32%) |
HCI: Huntsman Cancer Institute; U of M: University of Michigan; Penn: University of Pennsylvania